Drug intelligence / Profile preview

RP-102124

Development stage: Unknown
Lead developer: Revere Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

RP-102124 is a first-in-class, orally bioavailable small molecule that acts as an allosteric inhibitor of RAC1, a member of the Rho family of GTPases. It has demonstrated potent inhibition of tumor growth in xenograft models and enhances the activity of standard-of-care therapies such as irinotecan in preclinical studies. The compound was initially developed by Revere Pharmaceuticals and is currently at the IND (Investigational New Drug) application stage for oncology indications[2][4][1].

Targets

RAC1 (Rac family small GTPase 1)

Beyond the preview

Go deeper on RP-102124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP-102124.

Explore the full profile